1. Drug Policy in Bulgaria
Antoniya Dimova, PhD, Maria Rohova, PhD, Elka Atanasova, PhD, Paweł Kawalec, MD, PhD, Katarzyna Czok, MSc 
Value in Health Regional Issues 
Volume 13, Pages (September 2017)
DOI: /j.vhri
Copyright © Terms and Conditions

2. Fig. 1
Flowchart of the reimbursement decision-making process. HTA, health technology assessment; INN, international nonproprietary name; MAH, marketing authorization holder; MoH, Ministry of Health; NHIF, National Health Insurance Fund; PDL, positive drug list.
Value in Health Regional Issues  , 50-54DOI: ( /j.vhri )
Copyright © Terms and Conditions